Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares of 45.65M shares in Q2 FY2026
Q2 FY2026 weighted avg shares was 45.65M shares.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 43.03M USD
- Year-over-year change
- +0.0%
- 1-year CAGR
- +0.0%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.03M | +0.0% |
| FY2024 | 2024-12-31 | 43.03M | — |
Weighted Avg Shares vs competitors
How ATTO compares with its peers on the latest reported figures
- ATTO's FY2025 weighted avg shares of 43.03M shares is the 7th highest of the 11 companies compared; the peer median is 58.34M shares.
- Its year-over-year change of +0.0% is the 8th highest of 10, against a peer median of +5.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 124.17M | +37.8% | +23.4% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | 115.39M | +93.7% | +384.0% |
ZURAZura Bio Limited | LTM Mar 2026 | 98.81M | +34.9% | +76.1% |
| LTM Mar 2026 | 65.6M | +4.1% | +30.0% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | 61.01M | +68.6% | +46.8% |
| FY2025 | 55.66M | +0.8% | +0.4% | |
| FY2025 | 43.03M | +0.0% | — | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | 36.24M | +0.0% | — |
EVMNEvommune, Inc. | LTM Mar 2026 | 31.7M | — | — |
| LTM Mar 2026 | 28.59M | -2.5% | -0.4% | |
| LTM Mar 2026 | 12.77M | +5.5% | +56.8% | |
| Peer median (excluding ATTO) | 58.34M | +5.5% | +38.4% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 1.35M |
| Cost of Revenue | 313K | 804K |
| Gross Profit | (313K) | 546K |
| Gross Margin | — | 40.4% |
| Research & Development | 33.86M | 54.15M |
| Selling, General & Admin | 7.38M | 13.55M |
| Operating Expenses | 41.24M | 67.71M |
| Depreciation & Amortization | 313K | 804K |
| EBITDA | (41.24M) | (66.36M) |
| EBITDA Margin | — | -4915.2% |
| Operating Income | (41.55M) | (67.16M) |
| Operating Margin | — | -4974.7% |
| Interest Income | 3.44M | 6.63M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 1.75M | 6.53M |
| Income Before Tax | (39.8M) | (60.63M) |
| Pre-Tax Margin | — | -4490.9% |
| Income Tax Expense | 0 | 0 |
| Net Income | (39.8M) | (60.63M) |
| Net Margin | — | -4490.9% |
| EPS (Basic) | (1.05) | (1.42) |
| EPS (Diluted) | (1.05) | (1.42) |
| Weighted Avg Shares | 43.03M | 43.03M |
| Weighted Avg Shares (Diluted) | 43.03M | 43.03M |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.